Lupin acquires this French Pharma company

The acquisition of Medisol is part of our strategy to expand our presence in the EU and accelerate our Injectables franchise in France.” 

229
Lupin

Last Updated on May 8, 2023 by The Health Master

Global pharma major Lupin, headquartered in Mumbai, has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, for over Rs 160 crore, subject to approval from the French Ministry of Economy and Finance.

Founded in 2011, Medisol specialises in Generics Injectable products and is engaged in developing and commercialising its products in France, in pharmacies and in hospitals.

With this acquisition, Lupin will gain access to Medisol’s portfolio of seven injectable products across four therapeutic areas, including:

  • Pain management,
  • Anti-inflammatory,
  • Cardiovascular diseases,
  • Obstetrics.

Commenting on the acquisition, Vinita Gupta, CEO, Lupin said, “The acquisition of Medisol is part of our strategy to expand our presence in the EU and accelerate our Injectables franchise in France.” 

Thierry Volle, President – EMEA, Lupin added, “The acquisition of Medisol marks a significant milestone in Lupin’s journey to strengthen our injectables portfolio in France, the second-largest market in Europe for injectables.”

“Medisol’s unique product portfolio complements our existing range, enabling us to offer our customers an even more robust selection of high-quality products.”

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news